1. Pink Sheet
  2. >>Geography
  3. >>Europe

UK Explores Feasibility Of 100% Trial Registration Rates In Major Transparency Push

 
• By Vibha Sharma

By the end of this year, the UK's Health Research Authority plans to have developed a strategy to drive improvements in research transparency, particularly when it comes to the registration of clinical trials and making results public.

Clinical trials
The HRA Is Taking Steps To Improve Clinical Trial Transparency • Source: Shutterstock

The UK's Health Research Authority is stepping up efforts to achieve "full clinical trial transparency" and has begun work on developing a detailed strategy to explain how it will go about doing this.

The HRA plans to submit its final transparency strategy – including clear deadlines and milestones – to the House of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe

EU Ups Ante On Stockpiling For Crises

 
• By Francesca Bruce

The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 
• By Francesca Bruce

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines Agency 30th anniversary.

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 
• By Neena Brizmohun

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.